Bronchogenic Carcinoma

• EMA withdrawal · 2017-11-10
  EMA Application withdrawn: Kyomarc (bevacizumab) — Amgen Europe B.V.

  The EMA withdrew the application for Kyomarc (bevacizumab) from Amgen Europe B.V., relating to several carcinomas and neoplasms.

• CLINICAL_TRIALS trial_result · 2006-12-04
  Clinical Trial Update: Randomized Trial of Fluticasone in Bronchial Premalignancy [Phase 2]

  This document reports the completion of a Phase 2 randomized trial evaluating inhaled fluticasone in bronchial premalignancy related to bron…